Latham & Watkins Advises SQZ Biotechnologies in its Initial Public Offering

A capital markets deal team advised the cell therapy company in the offering.

November 03, 2020

SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”) has announced the pricing of its initial public offering of 4,411,765 shares of common stock at a public offering price of US$16.00 per share. All of the shares of common stock are being offered by SQZ. In addition, SQZ has granted the underwriters a 30-day option to purchase up to an additional 661,764 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any. SQZ’s common stock trades on the New York Stock Exchange under the ticker symbol “SQZ.” 

Latham & Watkins LLP represented SQZ Biotechnologies Company in the transaction with a capital markets deal team led by partners Peter Handrinos and Wesley Holmes, with associates Jennifer Yoon, N. Danny Shulman, and Michael Casagrande. Advice was also provided on benefits and compensation matters by partner Matthew Conway, with associate Kirk Porter; on technology transactions matters by partner Alan Tamarelli, with associate Seth Appiah-Opoku; on FDA regulatory matters by partner Ben Haas and counsel Betty Pang, with associates Chad Jennings, Barrett Tenbarge, and Kiera Murphy; on tax matters by partner Jocelyn Noll, with associate Michael Yu; and on other corporate matters by partner Jenna Cooper, with associate Justin McNamee. 


 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.